远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00512 远大医药

未开盘 07-29 16:08:21

5.140

+0.020

+0.39%

最高5.200	最低5.080	成交量301.73万
今开5.090	昨收5.120	日振幅2.34%
总市值182.47亿	流通市值182.45亿	总股本35.50亿
成交额1,549万	换手率0.09%	流通股本35.50亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00512","market":"HK","secType":"STK","nameCN":"远大医药","latestPrice":5.14,"timestamp":1785312501000,"preClose":5.12,"halted":0,"volume":3017282,"delay":0,"changeRate":0.0039062499999999167,"floatShares":3549571148,"shares":3550000000,"eps":0.3544,"marketStatus":"未开盘","change":0.02,"latestTime":"07-29 16:08:21","open":5.09,"high":5.2,"low":5.08,"amount":15492429,"amplitude":0.023438,"askPrice":5.14,"askSize":14000,"bidPrice":5.13,"bidSize":39000,"shortable":3,"etf":0,"ttmEps":0.3544,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785375000000},"marketStatusCode":0,"adr":0,"listingDate":819302400000,"exchange":"SEHK","adjPreClose":5.12,"dividendRate":0.032879,"openAndCloseTimeList":[[1785288600000,1785297600000],[1785301200000,1785312000000]],"volumeRatio":0.8593537192732157,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00512","defaultTab":"news","newsList":[{"id":"2653757741","title":"远大医药：抑郁症中药创新药GPN01360III期临床完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2653757741","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653757741?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:50","pubTimestamp":1784803800,"startTime":"0","endTime":"0","summary":"7月23日，远大医药（00512）发布公告，公司用于治疗抑郁症的中药创新药GPN01360在中国开展的III期临床研究完成了首例患者入组给药。该研究计划入组480例抑郁症患者，口服给药8周，旨在评估GPN01360相较于安慰剂治疗抑郁症的有效性、安全性和耐受性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233819076010.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233819076010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","LNGR","00512","BK1161","06978","IBBQ","MEDX","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653483749","title":"远大医药(00512.HK)掘金百亿中药治疗抑郁症创新赛道 GPN01360国内III期临床完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2653483749","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653483749?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:35","pubTimestamp":1784802907,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653746799","title":"远大医药(00512.HK)：中药1.1类创新药GPN01360在中国开展的III期临床研究完成首例患者入组给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2653746799","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653746799?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:20","pubTimestamp":1784802025,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["00512","BK1574","BK1191","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135948158","title":"远大医药创新中药GPN01360在华III期临床完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1135948158","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135948158?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:16","pubTimestamp":1784801787,"startTime":"0","endTime":"0","summary":"2026年7月23日，远大医药集团有限公司发布自愿公告称，其用于治疗抑郁症的1.1类中药创新药GPN01360已在中国III期临床研究中完成首例患者入组并给药。该项目被列入国家“重大新药创制”专项。据公告，III期研究为随机、双盲、安慰剂平行对照、多中心设计，计划入组480例抑郁症患者，口服给药8周。GPN01360源自古代方剂“逍遥散”，处方由柴胡、郁金、佛手等12味中药组成，具有疏肝健脾、解郁安神功效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649617239","title":"港股异动 | 远大医药(00512)涨超4% 合作伙伴全球首创核药TLX591-Tx再传佳音 临床数据获得验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2649617239","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649617239?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:16","pubTimestamp":1783304170,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，远大医药涨超4%，截至发稿，涨3.5%，报5.33港元，成交额759.19万港元。此前，在2026年ASCO年会上公布的ProstACT Global第一部分主要研究结果显示，TLX591-Tx联合标准疗法安全性、耐受性良好，血液学事件短暂可控，关键器官辐射暴露安全，药物肿瘤滞留性优异且无明显药物间相互作用。同时，与其他PSMA靶向小分子放射性配体疗法相比，TLX591-Tx治疗展现出了不同的靶向性和药理学特性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1191","BK4585","KCAI","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648133653","title":"远大医药(00512.HK)合作伙伴全球首创核药TLX591-Tx再传佳音 核药龙头带来前列腺癌治疗新希望","url":"https://stock-news.laohu8.com/highlight/detail?id=2648133653","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648133653?lang=zh_cn&edition=full","pubTime":"2026-07-03 13:10","pubTimestamp":1783055459,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648065318","title":"远大医药(00512)合作伙伴全球首创核药TLX591-Tx再传佳音 核药龙头带来前列腺癌治疗新希望","url":"https://stock-news.laohu8.com/highlight/detail?id=2648065318","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648065318?lang=zh_cn&edition=full","pubTime":"2026-07-03 13:10","pubTimestamp":1783055459,"startTime":"0","endTime":"0","summary":"随着TLX591-Tx全球临床的持续推进，有望全球前列腺癌患者提供全新的精准治疗选择。预计2030年，全球前列腺癌药物市场将增至345亿美元，复合年增长率约10.5%。管线矩阵多点开花，持续深化全链条核药发展体系TLX591-Tx此次披露的积极临床数据，印证了放射性核素药物治疗前列腺癌的临床价值，也凸显出远大医药锚定核药赛道布局的前瞻性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK0188","BK0196","BK0183","BK0238","BK0012","BK1191","BK0028","000876","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192642271","title":"远大医药6月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1192642271","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192642271?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:22","pubTimestamp":1782984166,"startTime":"0","endTime":"0","summary":"7月2日，远大医药发布截至2026年6月30日的股份变动月报表。公告显示，公司本月无新增发行、回购或注销股份，股本整体维持不变。已发行股本及库存股方面，与上月一致，已发行普通股股份数目为3,549,571,148股，库存股份数目为0股，合计3,549,571,148股。截至6月末，远大医药股本总数保持稳定，未有新增发行及回购活动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197835522","title":"远大医药与华东医药等达成协议 将供应药品制剂及原料等","url":"https://stock-news.laohu8.com/highlight/detail?id=1197835522","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197835522?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:07","pubTimestamp":1780909621,"startTime":"0","endTime":"0","summary":"根据一项新达成的协议，远大医药（中国）有限公司将向华东医药股份有限公司及其他相关方供应药品制剂、原料药及其他相关产品。\n此项合作旨在整合双方在医药领域的资源与优势，通过稳定的供应链安排，保障相关药品及原料的及时供应。协议的履行预计将对双方的业务发展产生积极影响。\n远大医药作为供应方，其产品线覆盖范围及生产能力是此项合作的基础。而华东医药等作为接收方，其市场渠道与分销网络将有助于相关产品的后续推广与销售。此次合作展现了医药企业间强化产业协同、优化资源配置的市场趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641175999","title":"远大医药(00512)核药合作伙伴重磅产品亮相ASCO 全球首创RDC药物硬核数据夯实全球竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2641175999","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641175999?lang=zh_cn&edition=full","pubTime":"2026-06-07 18:09","pubTimestamp":1780826974,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，远大医药核药领域的重要战略合作伙伴Telix Pharmaceuticals Limited 全球创新产品TLX591-Tx重磅亮相2026 ASCO年会，其治疗转移性去势抵抗性前列腺癌的全球III期临床试验的第一部分试验数据完成首次大会口头汇报，展现了该产品优异的临床安全性以及药代动力学特征，充分验证了该产品的临床潜力，未来或将为mCRPC精准治疗再添全新利器。WHO国际癌症研究机构发布的最新数据显示，2022年全球前列腺癌新发病例146.8万，死亡人数近40万。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","RDC","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126045583","title":"远大医药5月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1126045583","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126045583?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:41","pubTimestamp":1780483317,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司于2026年6月3日发布本公司截至2026年5月31日的股份变动月报表。报告显示，远大医药在此期间未进行新增发行、购回、注销或库藏股活动，股本保持稳定。根据公告，截至5月末，公司法定及注册股本维持为100,000,000,000股普通股，面值每股港币0.01元，相当于法定/注册股本总额港币10亿元。本次公告由公司秘书傅天忠签署。根据月报信息，截至5月31日，公司股本总数保持不变，未有股份发行及回购活动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637809470","title":"远大医药(00512)核药伙伴Telix创新产品TLX101治疗初诊原发性胶质母细胞瘤海外I期研究迎关键进展 全球脑癌治疗再树新标杆","url":"https://stock-news.laohu8.com/highlight/detail?id=2637809470","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637809470?lang=zh_cn&edition=full","pubTime":"2026-05-21 12:55","pubTimestamp":1779339306,"startTime":"0","endTime":"0","summary":"TLX101已获得美国FDA授予孤儿药资格认定，是全球范围内极具潜力的脑胶质瘤创新治疗方案。这标志着TLX101将成为首个进入胶质母细胞瘤III期开发的放射性药物疗法，临床开发进程持续领跑全球。未来若远大医药TLX101开发进展顺利，则有望提供全新的胶质母细胞瘤治疗手段，并为公司提供新的业绩增长点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"远大医药(00512)核药伙伴Telix创新产品TLX101治疗初诊原发性胶质母细胞瘤海外I期研究迎关键进展 全球脑癌治疗再树新标杆","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635204903","title":"【券商聚焦】平安证券维持远大医药(00512)“推荐”评级 指其创新产品收入占比提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2635204903","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635204903?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:40","pubTimestamp":1778661600,"startTime":"0","endTime":"0","summary":"金吾财讯 | 平安证券发布研报指，远大医药 2015年集采阶段性影响出清，公司创新和壁垒产品收入占比提升至50%左右，较上年提升近10个百分点。核药抗肿瘤及心脑血管介入产品收入12.82亿港元，同比增长约57.1%，其中核药抗肿瘤板块收入约9.49亿港元，同比增长61.0%，表现亮眼。公司自主研发的FAP靶点小分子RDC药物GPN01530获FDA批准开展用于实体瘤诊断的1/2期临床。维持\"推荐\"评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981292","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170596331","title":"远大医药4月股份变动月报，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1170596331","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170596331?lang=zh_cn&edition=full","pubTime":"2026-05-04 16:49","pubTimestamp":1777884554,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司于2026年5月4日发布2026年4月股份变动月报，报告期为2026年4月1日至4月30日。公告显示，截至2026年4月30日，公司法定股本为100,000,000,000股普通股，面值每股港币0.01元，对应法定股本总额为港币1,000,000,000元。报告期内，已发行普通股股数合计为3,549,571,148股，与上月保持一致，库存股数量继续为0股，未发生新增发行、购回或注销等行为。公司同时确认，截至4月末，其公众持股量符合相关上市规则要求。本次月报由公司秘书傅天忠签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174844680","title":"远大医药（00512）2025年收入升至122.83亿元，核心业务稳步增长聚焦全球化与创新研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1174844680","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174844680?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:10","pubTimestamp":1777464657,"startTime":"0","endTime":"0","summary":"远大医药在最新年度报告中显示，2025年度实现收益122.83亿元，同比增长约5.48%。分业务来看，涵盖肿瘤、危重症、心脑血管、呼吸及五官科等多元化治疗领域的核心板块持续发力，创新药与仿制药研发同步推进，重点项目包括STC3141、FAP靶蛋白新型治疗方案、GPN01530、GPC-3及N2006等。从全年经营层面看，远大医药在专注提升运营效率的同时，通过多宗并购和资源整合，强化了呼吸、抗肿瘤及心脑血管等重点治疗领域的布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"远大医药（00512）2025年收入升至122.83亿元，核心业务稳步增长聚焦全球化与创新研发","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146031355","title":"远大医药拟回购不超过10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1146031355","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146031355?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:06","pubTimestamp":1777464409,"startTime":"0","endTime":"0","summary":"远大医药日前公告称，董事会已向股东提议，于即将召开的股东大会上申请授权回购最高不超过公司已发行股本总数10%的股份。根据公告，截至最后可行日期，远大医药已发行股份总数约为3,549,571,148股，若授权获批，最多可回购约354,957,114股。远大医药同时提醒股东，公司将于6月2日至5日暂停办理股份过户手续，股东大会定于6月5日上午在香港中环中心召开，将就回购授权相关提案进行表决。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"远大医药拟回购不超过10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629046554","title":"董事会主席唐纬坤增持远大医药(00512)5万股 每股作价约6.47港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629046554","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629046554?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:56","pubTimestamp":1776855412,"startTime":"0","endTime":"0","summary":"香港联交所最新数据显示，4月22日，董事会主席唐纬坤增持远大医药(00512)5万股，每股作价6.472港元，总金额为32.36万港元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260422/20260422185722_69561.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260422/20260422185722_69561.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["EWH","BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627982064","title":"远大医药：易甘泰在美国开展的治疗HCC临床研究达到了临床终点 完全缓解率90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627982064","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627982064?lang=zh_cn&edition=full","pubTime":"2026-04-14 09:44","pubTimestamp":1776131040,"startTime":"0","endTime":"0","summary":"4月13日，远大医药（00512）发布公告，集团联营公司SirtexMedicalPtyLtd的SIR-Spheres钇[Y]微球注射液(\"易甘泰?\")在美国开展的用于治疗不可切除肝细胞癌(\"HCC\")临床研究(\"DOORwaY90研究\")成功达到了临床终点。该研究的结果显示，完全缓解率高达90%，最佳总体缓解率为99%，局部肿瘤控制率达100%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704050982.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704050982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","HCC","00512","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627455205","title":"“Go Global”再结硕果！远大医药(00512)钇[90Y]微球注射液美国临床达终点数据全球领先，驱动全球自主销售放量加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2627455205","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627455205?lang=zh_cn&edition=full","pubTime":"2026-04-13 21:16","pubTimestamp":1776086193,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，远大医药重磅核药SIR-Spheres钇[90Y]微球注射液(易甘泰)再度迎来里程碑进展！4月13日，远大医药发布公告称，公司钇[90Y]微球注射液在美国开展的用于治疗不可切除肝细胞癌临床研究已成功达到预设临床终点，取得了极为亮眼的临床数据。肝癌是全球第六大新发癌症以及第三大致死癌症。根据GLOBOCAN 2022年的数据，肝癌全球新发病例约87万，死亡病例约76万。此次钇[90Y]微球注射液成功达到海外临床","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"“Go Global”再结硕果！远大医药(00512)钇[90Y]微球注射液美国临床达终点数据全球领先，驱动全球自主销售放量加速","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625912121","title":"远大医药：与香港大学达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2625912121","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625912121?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:38","pubTimestamp":1775641120,"startTime":"0","endTime":"0","summary":"南财智讯4月8日电，远大医药（00512.HK）发布自愿公告，宣布与香港大学及其全资子公司港大科桥有限公司达成战略合作。双方将在学术研究、资源共享、人才培养及产品开发等方面深度合作，以创新抗菌药物开发为起点，由李学臣教授团队承接研发，旨在解决抗菌治疗领域未被满足的临床需求；后续香港大学将相关知识产权独家授权予远大医药，由其负责开发、注册及商业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604083698144219.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604083698144219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinagrandpharm.com","stockEarnings":[{"period":"1week","weight":-0.0338},{"period":"1month","weight":0.0776},{"period":"3month","weight":-0.145},{"period":"6month","weight":-0.3199},{"period":"1year","weight":-0.4245},{"period":"ytd","weight":-0.3225}],"compareEarnings":[{"period":"1week","weight":0.0368},{"period":"1month","weight":0.1208},{"period":"3month","weight":0.0012},{"period":"6month","weight":-0.0577},{"period":"1year","weight":0.0111},{"period":"ytd","weight":0.0069}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"远大医药集团有限公司是一家主要从事医药业务的投资控股公司。该公司主要从事制造及销售医药制剂及医疗器械。该公司还从事制造及销售生物技术产品、健康产品、精品原料药和其他产品。该公司的主要产品包括核药抗肿瘤诊疗及心脑血管介入诊疗科技产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.451613,"avgChangeRate":0.084145},{"month":2,"riseRate":0.709677,"avgChangeRate":0.104891},{"month":3,"riseRate":0.387097,"avgChangeRate":0.015748},{"month":4,"riseRate":0.612903,"avgChangeRate":0.013455},{"month":5,"riseRate":0.451613,"avgChangeRate":0.076266},{"month":6,"riseRate":0.354839,"avgChangeRate":-0.048729},{"month":7,"riseRate":0.387097,"avgChangeRate":-0.011661},{"month":8,"riseRate":0.4,"avgChangeRate":0.006591},{"month":9,"riseRate":0.466667,"avgChangeRate":-0.03929},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014639},{"month":11,"riseRate":0.5,"avgChangeRate":0.085072},{"month":12,"riseRate":0.5,"avgChangeRate":-0.007406}],"exchange":"SEHK","name":"远大医药","nameEN":"GRAND PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"远大医药,00512,远大医药股票,远大医药股票老虎,远大医药股票老虎国际,远大医药行情,远大医药股票行情,远大医药股价,远大医药股市,远大医药股票价格,远大医药股票交易,远大医药股票购买,远大医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}